


What is claimed is:



1. A compound of Formula (I):









or a pharmaceutically acceptable salt thereof, wherein:



R⁷ is a peptide;



R⁸ is selected from the group consisting of:








































Q is selected from the group consisting of











$R^1, R^2, R^3, R^4, R^5, R^6, R^9, R^{10}, R^{11}$, and R^{12} are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$, wherein said C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, C_{3-10} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, or 3 substituents

independently selected from halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};

or R¹ and R² together with the carbon atom to which they are attached form a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};

or R¹ and R³ together with the carbon atoms to which they are attached form a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};

or R² and R³ together with the carbon atoms to which they are attached form a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};


or R³ and R⁴ together with the carbon atom to which they are attached form a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};

or R⁵ and R⁶ together with the carbon atom to which they are attached form a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{bl}, C(O)NR^{cl}R^{dl}, C(O)OR^{al}, OC(O)R^{bl}, OC(O)NR^{cl}R^{dl}, NR^{cl}R^{dl}, NR^{cl}C(O)R^{bl}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{dl};

R¹³ is H or C₁₋₆ alkyl;

A is H or C₁₋₄ alkyl;

R^{a1}, R^{b1}, R^{c1}, and R^{d1} are each independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, OH, CN, NO₂, and CO₂CH₃; wherein said C₁₋₆ alkyl and C₂₋₆ alkenyl are each optionally substituted with OH, CN, NO₂, or CO₂CH₃;



is C₆₋₁₀ aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;

Ring G is a C₃₋₁₄ cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂, OR^{al}, SR^{al}, C(O)R^{b1}, C(O)NR^{cl}R^{d1}, C(O)OR^{al}, OC(O)R^{b1}, OC(O)NR^{cl}R^{d1}, NR^{cl}R^{d1}, NR^{cl}C(O)R^{b1}, NR^{cl}C(O)OR^{al}, and NR^{cl}C(O)NR^{cl}R^{d1};

$[N, O, S]$ is NH , O , or S ;

$[\mathbf{N}, \mathbf{O}]$ is $\mathbf{NH}$ or $\mathbf{O}$;


[C, N, O] is CR^XR^Y, NH, or O; and



each R^x and R^y are independently selected from H and C₁₋₄ alkyl.



2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:



R⁷ is a peptide;



R^8 is selected from the group consisting of:








































Q is selected from the group consisting of












, and



;

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^9 , R^{10} , R^{11} , and R^{12} are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, 5-10 membered heteroaryl, halo, CN, NO_2 , OR^{al} , SR^{al} , $C(O)R^{bl}$, $C(O)NR^{cl}R^{dl}$, $C(O)OR^{al}$, $OC(O)R^{bl}$, $OC(O)NR^{cl}R^{dl}$, $NR^{cl}R^{dl}$, $NR^{cl}C(O)R^{bl}$, $NR^{cl}C(O)OR^{al}$, and $NR^{cl}C(O)NR^{cl}R^{dl}$, wherein said C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{al} , SR^{al} , $C(O)R^{bl}$, $C(O)NR^{cl}R^{dl}$, $C(O)OR^{al}$, $OC(O)R^{bl}$, $OC(O)NR^{cl}R^{dl}$, $NR^{cl}R^{dl}$, $NR^{cl}C(O)R^{bl}$, $NR^{cl}C(O)OR^{al}$, and $NR^{cl}C(O)NR^{cl}R^{dl}$;

or R^1 and R^2 together with the carbon atom to which they are attached form a C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{al} , SR^{al} , $C(O)R^{bl}$, $C(O)NR^{cl}R^{dl}$, $C(O)OR^{al}$, $OC(O)R^{bl}$, $OC(O)NR^{cl}R^{dl}$, $NR^{cl}R^{dl}$, $NR^{cl}C(O)R^{bl}$, $NR^{cl}C(O)OR^{al}$, and $NR^{cl}C(O)NR^{cl}R^{dl}$;

or R^1 and R^3 together with the carbon atoms to which they are attached form a C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or R^2 and R^3 together with the carbon atoms to which they are attached form a C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;


or R^3 and R^4 together with the carbon atom to which they are attached form an C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or R^5 and R^6 together with the carbon atom to which they are attached form an C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

R^{13} is H or C_{1-6} alkyl;

A is H or C_{1-4} alkyl;

R^{a1} , R^{b1} , R^{c1} , and R^{d1} are each independently selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OH, CN, NO_2 , and CO_2CH_3 ; wherein said C_{1-6} alkyl and C_{2-6} alkenyl are each optionally substituted with OH, CN, NO_2 , or CO_2CH_3 ;



is C_{6-10} aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;

[N, O, S] is NH, O, or S;

[N, O] is NH or O;

[C, N, O] is $CR^X R^Y$, NH, or O; and

each R^X and R^Y are independently selected from H and C_{1-4} alkyl.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁷ is a peptide capable of selectively delivering R⁸Q- across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁷ is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5);

and wherein R⁷ is attached to Q through a cysteine residue of R⁷.

5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁷ is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2), and


ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),

and wherein R⁷ is attached to Q through a cysteine residue of R⁷.

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁷ is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).

7. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁷ is a peptide comprising the sequence: AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein Q is:



9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , and R^4 are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, 5-10 membered heteroaryl, halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$, wherein said C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$.


10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^3 together with the carbon atoms to which they are attached form a C_{3-14} cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C_{1-4} alkyl, halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$.

11. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^3 together with the carbon atom to which they are attached form a cyclopentyl, cyclohexyl, cycloheptyl, 1,2,3,4-tetrahydronaphthyl, tetrahydrofuranyl, or tetrahydropyranyl.


12. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^3 together with the carbon atom to which they are attached form a C_{3-7} cycloalkyl group.

13. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^3 together with the carbon atom to which they are attached form a cyclohexyl group.

14. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein Q is:




15. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein Q is:




16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each independently selected from H and methyl, and R^3 , R^4 , R^5 , and R^6 are each H.
17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each independently selected from H and methyl.
18. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each H.
19. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 together with the carbon atom to which they are attached form a C_{3-7} cycloalkyl group.
20. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 together with the carbon atom to which they are attached form a cyclobutyl group.
21. The compound of any one of claims 1-8 and 16-20, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each H.
22. The compound of any one of claims 1-8 and 16-20, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^4 are each H.
23. The compound of any one of claims 1-8 and 16-20, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are each H.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R^9 , R^{10} , R^{11} , and R^{12} are each independently selected from H and methyl.

25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R^9 , R^{10} , R^{11} , and R^{12} are each H.

26. The compound of any one of claims 1-25, wherein R^8 is:



27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

R^7 is a peptide;

R^8 is a topoisomerase I inhibitor;

Ring Z is a monocyclic C_{5-7} cycloalkyl ring or a monocyclic 5-7 membered heterocycloalkyl ring;

each R^Z is independently selected from C_{1-4} alkyl, halo, CN, NO_2 , OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or two adjacent R^Z together with the atoms to which they are attached form a fused monocyclic C_{5-7} cycloalkyl ring, a fused monocyclic 5-7 membered heterocycloalkyl ring, a fused C_{6-10} aryl ring, or a fused 6-10 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from C_{1-4} alkyl, halo, CN, NO_2 ,

OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$.

R^{a1} , R^{b1} , R^{c1} , and R^{d1} are each independently selected from H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, OH, CN, and NO_2 ; and

n is 0, 1, 2, or 3.

28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

29. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R^7 is Pv1, Pv2, Pv3, Pv4, or Pv5.

30. The compound of any one of claims 27-29, or a pharmaceutically acceptable salt thereof, wherein R^7 is attached to the core via a cysteine residue of R^7 wherein one of the sulfur atoms of the disulfide moiety in Formula II is derived from the cysteine residue.

31. The compound of any one of claims 27-30, or a pharmaceutically acceptable salt thereof, wherein R^8 is camptothecin, opotecan, irinotecan (CPT-11), silatecan (DB-67, AR-67), cositecan (BNP-1350), lurtotecan, gimatecan (ST1481), belotecan (CKD-602), rubitecan, topotecan, deruxtecan, or exatecan.

32. The compound of any one of claims 27-30, or a pharmaceutically acceptable salt thereof, wherein R^8 is exatecan.

33. The compound of any one of claims 27-31, or a pharmaceutically acceptable salt thereof, wherein R^8 is attached to the core through an N atom.

34. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a monocyclic C₅₋₇ cycloalkyl ring.
35. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cyclopentyl ring.
36. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cyclohexyl ring.
37. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cycloheptyl ring.
38. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a monocyclic 5-7 membered heterocycloalkyl ring.
39. The compound of any one of claims 27-33, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 5-membered heterocycloalkyl ring.
40. The compound of any one of claims 27-30, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 6-membered heterocycloalkyl ring.
41. The compound of any one of claims 27-30, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 7-membered heterocycloalkyl ring.
42. The compound of any one of claims 27-41, or a pharmaceutically acceptable salt thereof, wherein two adjacent R^Z together with the atoms to which they are attached form a fused monocyclic C₅₋₇ cycloalkyl ring, a fused monocyclic 5-7 membered heterocycloalkyl ring, a fused C₆₋₁₀ aryl ring, or a fused 6-10 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from C₁₋₄ alkyl, halo, CN, NO₂,

OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$.



43. The compound of any one of claims 27-41, or a pharmaceutically acceptable salt thereof, wherein n is 0.


44. The compound of any one of claims 27-41, or a pharmaceutically acceptable salt thereof, wherein n is 1.

45. The compound of any one of claims 27-42, or a pharmaceutically acceptable salt thereof, wherein n is 2.

46. The compound of any one of claims 27-42, or a pharmaceutically acceptable salt thereof, wherein n is 3.


47. The compound of claim 27-33 and 42-46, wherein the compound has Formula (III), Formula (IV), or Formula (V):













or a pharmaceutically acceptable salt thereof.

48. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is selected from:























49. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is selected from:


















, and



50. A pharmaceutical composition that comprises a compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof.
51. A method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof.
52. The method of claim 51, wherein the cancer is selected from bladder cancer, bone cancer, glioma, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, epithelial cancer, esophageal cancer, Ewing's sarcoma, pancreatic cancer, gallbladder cancer, gastric cancer, gastrointestinal tumors, head and neck cancer, intestinal cancers, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer, lung cancer, melanoma, prostate cancer, rectal cancer, renal clear cell carcinoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, and uterine cancer.
53. The method of claim 51, wherein the cancer is selected from breast cancer, colorectal cancer, and gastric cancer.
54. The method of claim 52 or 53, wherein the breast cancer is triple-negative breast cancer.
55. A compound having the structure:



or a salt thereof.